The apicomplexan parasite Toxoplasma gondii, the causative agent of toxoplasmosis, is an important human pathogen. 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate isoprene biosynthesis pathway is essential to the organism and therefore a target for developing anti-toxoplasmosis drugs. In order to find potent inhibitors, we expressed and purified recombinant T. gondii DXR (TgDXR). Biochemical properties of this enzyme were characterized and an enzyme activity/inhibition assay was developed. A collection of 11 compounds with a broad structural diversity were tested against TgDXR and several potent inhibitors were identified with K i values as low as 48 nM. Analysis of the results as well as those of Escherichia coli and Plasmodium falciparum DXR enzymes revealed a different structure-activity relationship profile for the inhibition of TgDXR.
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The unicellular protozoan parasite Toxoplasma gondii, the causative agent of toxoplasmosis, is an important human pathogen. 1 In healthy adults, toxoplasmosis typically only produces mild, flu-like symptoms and the parasite becomes dormant. However, three factors make T. gondii a threat to public health. First, the parasite is highly promiscuous, infecting almost all warm-blooded animals including humans, with cats being the definitive host. Humans are infected by contacting cat feces contaminated with the mature oocyst form or by consumption of undercooked meat carrying tissue cysts. It is estimated that $30% of world population is chronically infected with T. gondii. A recent CDC (Centers for Disease Control and Prevention) report disclosed that the prevalence of this infection in the US is $11%. 1,2 Second, approximately one third of women infected for the first time with T. gondii during pregnancy will pass the parasite to the fetus where it can cause serious neurological damage to the fetus. Infection in particular the first trimester can lead to stillbirth. Third, the parasite poses a significant threat to immunocompromised persons, such as HIV-AIDS, cancer or organ transplant patients. Under these conditions latent infection can reactivate to fulminant Toxoplasma encephalitis, a life-threatening condition.
Immunocompromised patients therefore may require recurrent treatment as current treatments are unable to clear the chronic infection. This is also true for immunocompetent patients suffering from recurring ocular toxoplasmosis. Current therapy is largely limited to anti-folate therapy. Long-term use of sulfonamides in particular has significant side effects including hypersensitivity. New therapeutic agents are therefore needed to treat toxoplasmosis. 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the MEP (2-C-methyl-D-erythritol-4-phosphate) isoprene biosynthesis pathway is a novel target for developing anti-infective drugs. [3] [4] [5] As shown in Figure 1 are shown in Figure 2 . None of these DXR inhibitors showed activity against T. gondii growth. This was surprising considering our finding that T. gondii DXR (TgDXR) is essential to the growth of this organism. 22 T. gondii resistance to fosmidomycin is due to limited drug uptake, as previously found for certain bacteria. 23, 24 The parasite cell membrane represents a permeability barrier for the compound. This is supported by the observation that fosmidomycin can effectively kill a strain of T. gondii engineered to express the bacterial GlpT, a known transporter of fosmidomycin, thus validating TgDXR as a target for developing novel anti-toxoplasmosis drugs. 22 Here, we report the expression, purification and biochemical characterization of recombinant T. gondii DXR (TgDXR). The inhibitory activity as well as structure-activity relationships of TgDXR inhibitors are also presented. First, we performed multiple protein alignments of the putative TgDXR (NCBI Reference Sequence: XP_002370806.1) with Escherichia coli (Ec) and Plasmodium falciparum (Pf) DXRs, and the result is shown in Figure 3 . Similar to PfDXR, TgDXR was found to carry an additional 67 amino acid residue extension at the N-terminal, when compared with the E. coli enzyme. This sequence likely represents the bipartite apicoplast targeting peptide, 8 since both proteins localize to the apicoplast of the parasites. In addition, TgDXR possesses a very long linking sequence (224-285) with 62 residues between the NADPH binding domain (68-223) and the metal/substrate binding domain (286-513). However, in EcDXR and PfDXR, no more than 13 amino acid residues, which are mostly located in an a-helix that is away from the enzyme's active site, link the two domains. Nevertheless, the low homology among these three linker peptides (Fig. 3) as well as the structural information from EcDXR and PfDXR suggest the segment 224-285 of TgDXR may not be important for enzyme activity. Except for these differences, these three enzymes share an overall high degree of similarity. We next cloned the catalytic domain (68-513) of TgDXR and inserted it into the expression plasmid pET24b. The plasmid was transformed into E. coli BL21-CodonPlus strain and cultured in LB medium containing kanamycin and chloramphenicol. 25 His6-tagged recombinant TgDXR was expressed and purified using a standard Ni-affinity column chromatography to $90% purity, showing an apparent molecular mass of $45 kDa (Supplementary data on-line Fig. S1 ).
The recombinant enzyme was biochemically characterized and found to be able to catalyze the conversion of DXP to MEP in the presence of Mg 2+ and NADPH. 26 The reaction rate was monitored at 340 nm, where NADPH UV absorbance is maximal. First, the activity was tested in a HEPES buffer (50 mM, pH 7.6) containing
TgDXR (100 nM), DXP (100 lM), NADPH (100 lM), 50 lg/mL BSA (bovine serum albumin) and varying concentrations of MgCl 2 . As shown in Figure 4a , the activity of . We noted that activity of the enzyme can also be supported by Mn 2+ and Co 2+ , two additional commonly used divalent metal ions, as illustrated in Figure 4b . In the presence of Mn 2+ (2 mM)
TgDXR exhibits essentially the same activity as with Mg 2+ , and
shows approximately half of the activity with Co 2+ (2 mM). In addition, we measured the pH-dependence of TgDXR and the results demonstrated a pH optimum of 7.5-8.0 for this enzyme (Fig. 4c) , although significant activity can be observed for a range from pH 6.5 to 8.5. We next determined the K m value for the substrate DXP, which is necessary for the calculation of K i values (inhibition constant) of TgDXR inhibitors. Enzyme activities were measured in the presence of increasing concentrations of DXP (from 10 to 450 lM) and, as shown in Figure 4d , the K m value of TgDXR for DXP was determined to be 25.5 ± 3.7 lM when fitted into Michaelis-Menten equation. This is comparable to K m values of EcDXR (99 lM), 13 PfDXR (106 lM) 15 and Mycobacterium tuberculosis DXR (47 lM).
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Upon optimization of the TgDXR enzyme assay conditions, the inhibitory activity of compounds 1-11 ( Fig. 2) was determined in order to explore their structure-activity relationships (SAR) for this enzyme. 26 These selected compounds represent a broad structural diversity and are particularly suited for the initial SAR study. idomycin (1) and FR900098 (2) are highly polar phosphonohydroxamic acids, while compounds 3-9 possess more lipophilic properties. Compounds 3 and 4 are phosphonate DXR inhibitors with a pyridine-containing, lipophilic side chain, which was found to be essential for inhibiton. 12 Hydroxypyridinone compound 5 is the only potent DXR inhibitor without a phosphonate/phosphate group, which also exhibits broad antibacterial activity. 11 Pyridine-containing fosmidomycin derivatives 6-9 were recently found to have considerably higher activity against PfDXR as well as the proliferation of P. falciparum, 14 as compared to fosmidomycin. Analogous compounds 10 and 11 possess a 3,4-dichlorophenyl substituent at the a-position, which were also reported to possess potent antimalarial activities.
IspD -IspH
16 Table 1 summarizes the K i values of compounds 1-11 against the DXR enzymes of T. gondii, E. coli and P. falciparum. Fosmidomycin (1) and FR900098 (2) (Table 1) . However, the non-phosphonate compound 5 exhibits only very weak inhibitory activity against TgDXR (as observed for PfDXR, the other eukaryotic species) with a K i value of 25.6 lM. This could explain that despite its high lipophilicity, compound 5 does not block proliferation of T. gondii using our previous method, 22 although it possesses broad antibacterial activity including E. coli presumably due to its strong activity against EcDXR.
11 Pyridinecontaining compounds 6 and 7 with a formyl group are potent inhibitors of TgDXR with K i values of 55 and 79 nM, respectively, being more active than their parent compound fosmidomycin. This
shows that an appropriate a-substituent may provide favorable interactions with the T. gondii enzyme, as also observed for EcDXR and PfDXR. Surprisingly, the acetyl analogs, compounds 8 and 9, exhibit on average $11-fold less activity than compounds 6 and 7, suggesting that with an a-substituent, the terminal methyl group is disfavored on binding to TgDXR. This feature is quite different from those of EcDXR and PfDXR, for which 8 and 9 show similar or even higher activities as compared to their formyl analogs 6 and 7 (Table 1) . The same SAR is observed for compounds 10 and 11 against TgDXR, with a formyl group (K i = 77 nM) in 10 showing considerably more inhibitory activity than compound 11 with an acetyl moiety (K i = 220 nM). Figure 5 illustrates the plots of the inhibitory activities of compounds 1-11 against TgDXR with those against EcDXR and PfDXR. scribed above also show a different profile for TgDXR inhibition. These comparisons suggest that more biochemical, structural and pharmacological studies of TgDXR are needed to develop effective anti-toxoplasmosis drugs. The methods reported here for expression and inhibition of recombinant TgDXR could therefore be useful for these studies as well as high-throughput screening for potent inhibitors of the enzyme. In summary, this work is of interest for several reasons. Our previous studies validated DXR as a drug target for treating toxoplasmosis. We therefore expressed and purified recombinant TgDXR, which was found to be enzymatically active. Importantly, we directly support our previous assumption that TgDXR is fully susceptible to fosmidomycin. 22 TgDXR was observed to exert maximal activity in the presence of 4 mM Mg 2+ at pH 7.5-8.0. At these conditions, the K m value for the substrate DXP was determined to be 25.5 lM. A collection of 11 compounds were tested against TgDXR and several potent inhibitors were identified with K i values as low as 48 nM. Analysis of these results as compared to those of EcDXR and PfDXR revealed a different structure-activity relationship profile for the inhibition of TgDXR.
600 nm, TgDXR expression was induced by adding 0.25 mM isopropylthiogalactoside (IPTG) for 4 h at 37°C. Cells were then harvested and resuspended in 50 mM NaH 2 PO 4 (pH 8.0), 300 mM NaCl (buffer A) containing 20 mM imidazole. After addition of 0.2 mM phenylmethylsulfonyl fluoride and sonication at 0°C, the lysate was centrifuged at 20,000 rpm for 25 min and the supernatant was collected and subjected to an affinity column chromatography using the Ni-affinity column chromatography (HiTrap IMAC FF from GE Healthcare). The resin was washed with 30 mM imidazole in buffer A and then the protein was eluted with 300 mM imidazole in buffer A. After desalting (HiTrap Desalting, GE Healthcare) to 20 mM Tris pH 7.5, 150 mM NaCl, 2% glycerol, the protein was concentrated and stored in small aliquots at À80°C. 26. The enzyme activity was determined in 96-well microplates using purified TgDXR (100 nM), 4 mM MgCl 2 , 100 lM DXP, 100 lM NADPH in 50 mM HEPES buffer (pH 7.6) containing 50 lg/mL bovine serum albumin (BSA). For inhibition assays, compounds were incubated with TgDXR for 10 min at 30°C before adding DXP to initiate the reaction. The reaction rate was monitored at 340 nm using a Beckman DTX-880 microplate reader. The initial velocities of wells containing increasing concentrations of an inhibitor were calculated and imported into Prism (version 5.0, GraphPad Software, Inc., La Jolla, CA). The IC 50 values were then obtained by using a standard dose response curve fitting. 
